STOMP: Small cell lung cancer trial of olaparib (AZD2281) as maintenance programme - a randomised, double blind, multicentre NCRN phase II trial

被引：0
|
作者：
Woll, P. J. [1 ]
Jarrett, H. [2 ]
Billingham, L. [2 ]
机构：
[1] Univ Sheffield, Weston Pk Hosp, Sheffield S10 2TN, S Yorkshire, England
[2] Univ Birmingham, CRUK Clin Trials Unit, Birmingham B15 2TT, W Midlands, England
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70121-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
121
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [1] STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC
    Woll, Penella
    Gaunt, Piers
    Steele, Nicola
    Ahmed, Samreen
    Mulatero, Clive
    Shah, Riyaz
    Danson, Sarah
    Hodgkinson, Elizabeth
    James, Karen
    Watkins, Ben
    Fletcher, Peter
    Billingham, Lucinda
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S704 - S705
  • [2] Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
    Woll, Penella
    Gaunt, Piers
    Danson, Sarah
    Steele, Nicola
    Ahmed, Samreen
    Mulatero, Clive
    Shah, Riyaz
    Bhosle, Jaishree
    Hodgkinson, Elizabeth
    Watkins, Ben
    Billingham, Lucinda
    LUNG CANCER, 2022, 171 : 26 - 33
  • [3] Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
    Audeh, M. W.
    Penson, R. T.
    Friedlander, M.
    Powell, B.
    Bell-McGuinn, K. M.
    Scott, C.
    Weitzel, J. N.
    Carmichael, J.
    Tutt, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer
    Liu, J.
    Fleming, G. F.
    Tolaney, S. M.
    Birrer, M. J.
    Penson, R. T.
    Berlin, S. T.
    Whalen, C.
    Tyburski, K.
    Matijevich, K.
    Kasparian, E.
    Roche, M.
    Lee, H.
    Winer, E. P.
    Ivy, S. P.
    Matulonis, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
    Fennell, Dean A.
    Porter, Catharine
    Lester, Jason
    Danson, Sarah
    Blackhall, Fiona
    Nicolson, Marianne
    Nixon, Lisette
    Gardner, Georgina
    White, Ann
    Griffiths, Gareth
    Casbard, Angela
    ECLINICALMEDICINE, 2022, 52
  • [6] A RANDOMISED PHASE II TRIAL OF OLAPARIB MAINTENANCE VERSUS PLACEBO MONOTHERAPY IN PATIENTS WITH CHEMOSENSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fennell, Dean
    Casbard, Angela
    Lester, Jason
    Bridges, Sarah
    Griffiths, Gareth
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S894 - S895
  • [7] Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL)
    Massuti, Bartomeu
    Garcia Campelo, Rosario
    Rodriguez Abreu, Deivys
    Remon, Jordi
    Mejem, Margarita
    Galvez, Elisa
    Antonio Ortega, Jose
    Aparisi, Francisco
    Reguart, Noemi
    Angeles Sala, Maria
    Isla, Dolores
    Sanchez Ronco, Maria
    Verdu, Aria
    Angel Molina-Vila, Miguel
    Mayo-de las Casas, Clara
    Pereira, Eva
    Cajal, Rosana
    Gonzalez-Arenas, Maria Carmen
    Carcereny, Enric
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
    Postel-Vinay, S.
    Planchard, D.
    Granados, A. L. Ortega
    Gazzah, A.
    Gonzalez, M. A. Sala
    Majem, M.
    Camps, C. J.
    Abou-Lauvergne, A.
    Pignon, J-P.
    Cadranel, J.
    Bennouna, J.
    Barlesi, F.
    Campelo, M. R. Garcia
    Viteri, S.
    Besse, B.
    Sarto, J. Coves
    Sureda, B. Massuti
    Soria, J-C.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial
    Postel-Vinay, S.
    Planchard, D.
    Antigny, M.
    Coves Sarto, J.
    Domine Gomez, M.
    de las Penas Bataller, R.
    Sala Gonzalez, M. A.
    Viteri, S.
    Pozas Perez, J.
    Texier, M.
    Ortega Granados, A. L.
    Moran Bueno, M. T.
    Camps, C. J.
    Lopez-Martin, A.
    Provencio, M.
    Gazzah, A.
    Soria, J-C.
    Besse, B.
    Massuti Sureda, B.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S752 - S752
  • [10] Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
    Daniel, Davey
    Kuchava, Vladimer
    Bondarenko, Igor
    Ivashchuk, Oleksandr
    Reddy, Sreekanth
    Jaal, Jana
    Kudaba, Iveta
    Hart, Lowell
    Matitashvili, Amiran
    Pritchett, Yili
    Morris, Shannon R.
    Sorrentino, Jessica A.
    Antal, Joyce M.
    Goldschmidt, Jerome
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) : 2557 - 2570
12345